A5068005365- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Statistical Methods in Clinical Trials
- Hormonal and reproductive studies
- Advanced Radiotherapy Techniques
- Urologic and reproductive health conditions
- Bladder and Urothelial Cancer Treatments
- Global Cancer Incidence and Screening
- Cancer, Lipids, and Metabolism
- Genital Health and Disease
- Health Systems, Economic Evaluations, Quality of Life
- Radiomics and Machine Learning in Medical Imaging
- Colorectal Cancer Screening and Detection
- Effects of Radiation Exposure
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis B Virus Studies
- PARP inhibition in cancer therapy
- Multiple and Secondary Primary Cancers
- Urinary and Genital Oncology Studies
- Cancer Risks and Factors
- Urinary Bladder and Prostate Research
- Radiation Therapy and Dosimetry
- Economic and Financial Impacts of Cancer
- Urological Disorders and Treatments
- Cancer Genomics and Diagnostics
Brigham and Women's Hospital
2016-2025
Harvard University
2013-2025
Dana-Farber Cancer Institute
2016-2025
Dana-Farber Brigham Cancer Center
2014-2025
Salem State University
2022-2024
Massachusetts General Hospital
2003-2021
University of Connecticut
2003-2012
National Institutes of Health
2012
Beth Israel Deaconess Medical Center
2012
Regional Cancer Center
2011
ContextSurvival benefit in the management of high-grade clinically localized prostate cancer has been shown for 70 Gy radiation therapy combined with 3 years androgen suppression (AST), but long-term AST is associated many adverse events.ObjectiveTo assess survival 3-dimensional conformal (3D-CRT) alone or combination 6 months patients cancer.Design, Setting, and PatientsA prospective randomized controlled trial 206 who were to receive 3D-CRT (n = 104) 102) from December 1, 1995, April 15,...
Comorbidities may increase the negative effects of specific anticancer treatments such as androgen suppression therapy (AST).To compare 6 months AST and radiation (RT) to RT alone assess interaction between level comorbidity all-cause mortality.At academic community-based medical centers in Massachusetts, December 1, 1995, April 15, 2001, 206 men with localized but unfavorable-risk prostate cancer were randomized receive or combined. All-cause mortality estimates stratified by treatment...
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer management options localized, regional, metastatic disease. Recommendations disease monitoring, treatment recurrent disease, systemic therapy castration-recurrent also are included. This article summarizes the Panel's most significant discussions 2016 update guidelines, which include refinement stratification methods new men with high-risk very-high-risk progressive...
We evaluated whether the timing of fatal myocardial infarction (MI) was influenced by administration androgen suppression therapy (AST).The study cohort comprised 1,372 men who were enrolled onto three randomized trials between February 1995 and June 2001. In trials, randomly assigned to receive radiation with 0 versus 3 6, 8, or 6 months AST. Fine Gray's regression used determine clinical factors associated time MI, estimates MI calculated using a cumulative incidence method. When comparing...
Background: The relationship between prostate-specific antigen (PSA)–defined recurrence and prostate cancer–specific mortality remains unclear. Therefore, we evaluated the hypothesis that a short post-treatment PSA doubling time (PSA-DT) after radiation therapy is surrogate end point for by analyzing two multi-institutional databases. Methods: Baseline, treatment, follow-up information was compiled on cohort of 8669 patients with cancer treated surgery (5918 men) or (2751 from January 1,...
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis include management options localized, regional, metastatic disease. Recommendations disease monitoring treatment of recurrent are also included. Panel meets annually to reevaluate update their recommendations based on new clinical data input from within Member Institutions external entities. This article summarizes the panel’s discussions 2021 guidelines with regard systemic therapy...
Prostate cancer has surpassed lung as the most common in men United States. The NCCN Guidelines for Cancer provide multidisciplinary recommendations on clinical management of patients with prostate based evidence and expert consensus. Panel guidance treatment decisions localized disease is represented this version. Significant updates early include distinction between active surveillance observation, a new section principles imaging, revisions to radiation recommendations. full version these...
The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions regarding the workup of patients with prostate cancer, risk stratification and management localized disease, post-treatment monitoring, treatment recurrence advanced disease. sections included in this article focus metastatic castration-sensitive nonmetastatic castration-resistant cancer (CRPC), CRPC (mCRPC). Androgen deprivation therapy (ADT) intensification is strongly recommended cancer. For CRPC, ADT...
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer provide multidisciplinary recommendations the clinical management of patients with prostate cancer. These Insights highlight notable recent updates. Abiraterone acetate is a first-in-class hormonal agent that represents new standard care metastatic castration-recurrent cancer who have previously received docetaxel (category 1 recommendation). also category 2B prechemotherapy setting asymptomatic or...
The NCCN Guidelines for Prostate Cancer include recommendations staging and risk assessment after a prostate cancer diagnosis the care of patients with localized, regional, recurrent, metastatic disease. These Insights summarize panel's discussions 2024 update to guidelines regard initial stratification, management very-low-risk disease, treatment nonmetastatic recurrence.
The sensitivity and specificity of a screening test are biased when disease status is not verified in all subjects the likelihood confirmation depends on result itself. We assessed characteristics prostate-specific antigen (PSA) measurement after correction for verification bias.Between 1995 2001, 6691 men underwent PSA-based prostate cancer. Of these men, 705 (11 percent) subsequently biopsy prostate. Under assumption that chance undergoing only PSA-test other observed clinical variables,...
Men with localized prostate cancer and a preoperative prostate-specific antigen (PSA) velocity greater than 2.0 ng/mL per year experience 10-fold increase in cancer-specific mortality despite surgery.To assess whether 2.0-ng/mL PSA level during the prior to diagnosis was significantly associated following radiation therapy (RT).Between January 1, 1989, December 2002, 358 men treated RT for formed study cohort (median age at treatment, 71.2 [range, 43.2-83.5] years). A Cox regression...
To define methodology to show clinical benefit for patients in the state of a rising prostate-specific antigen (PSA).A states framework was used address hypothesis that definitive phase III trials could not be conducted this patient population.The Group focused on men with systemic (nonlocalized) recurrence and defined risk developing clinically detectable metastases. Models versus local recurrence, metastatic progression were discussed.Therapies have shown favorable effects more advanced...
Abstract BACKGROUND. The presence of multiple determinants aggressive cancer biology may impact prostate cancer‐specific mortality (PCSM) rates compared with fewer factors. authors estimated PCSM after radiation therapy short‐course androgen suppression (RT+AST) or radical prostatectomy (RP) in men clinically localized, intermediate‐risk to high‐risk cancer. METHODS. study cohort included 3240 treated from 1981 2002 RT 6 months AST (n = 550) RP 2690) for localized at least 1 risk factor...
Prostate specific antigen is a glycoprotein found almost exclusively in normal and neoplastic prostate cells. doubling time, or the change over has emerged as useful predictive marker for assessing disease outcome patients with cancer. It important to agree on definitions values calculation of develop common approach analysis reporting.In September 2006 conference was held at National Cancer Institute Bethesda, Maryland define these parameters guidelines their use.The Specific Antigen...
Multidisciplinary clinics offer a unique approach to the management of patients with cancer. Yet, limited data exist show that such affect management. The purpose this study was determine whether consultation at multidisciplinary clinic is associated selection active surveillance in low-risk prostate cancer.The comprised 701 men cancer managed three tertiary care centers Boston, MA 2009. Patients either obtained clinic, which they were seen by combination urologic, radiation, and medical...
Little is known regarding how patients select treatment for localized prostate cancer. This study examined determinants of patients' preferences health states related to cancer, and assessed whether and/or other factors predict choices.A survey 167 with newly diagnosed cancer was conducted in 4 academic medical practices from 2004 2007. The authors demographic factors, used a time-tradeoff method elicit the form quality-adjusted life years (QALYs) Linear regressions identified predictors (in...
Abstract BACKGROUND: The objective of this study was to evaluate the relation between kinetics prostate‐specific antigen (PSA) decline after initiation androgen‐deprivation therapy (ADT) and overall survival (OS) in men with metastatic, hormone‐sensitive prostate cancer (HSPC). METHODS: authors' institutional database used identify a cohort metastatic HSPC who were treated ADT. Patients included if they had at least 2 serum PSA determinations before nadir 1 value available within month ADT...